Fig. 1From: Distinct mutation profiles between primary bladder cancer and circulating tumor cells warrant the use of circulating tumors cells as cellular resource for mutation follow-upRepresentative immunostaining images showing circulating tumor cells (CTCs) with 4′,6-diamidino-2-phenylindole (DAPI), Vimentin, Cytokeratin, and CD45 positiveBack to article page